Bayer and Burrill Will Back Genomics-Based Diagnostics Ventures with $50 Million Fund | GenomeWeb

NEW YORK, Jan. 8 — Bayer Diagnostic and Burrill & Company said Tuesday that they had formed a new $50 million venture capital fund for diagnostic research. The fund particularly seeks to back new applications of pharmacogenomic and proteomic technology in the diagnostic field.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.